The purpose of this report is to evaluate the maintenance of efficacy and tolerability of etoricoxib over 52 weeks of treatment.
Diclofenac and etoricoxib have similar rates of cardiovascular events.
No episodes of upper GI perforation, ulceration or bleeding were reported in Part 1, although one patient receiving 90 mg etoricoxib had a serious lower GI bleed.
An initial trial of celecoxib CLASS 34 only considered upper GI endpoints with supratherapeutic doses 800 mg day of celecoxib compared to pooled data for the comparator NSAIDs diclofenac 75 mg BID and ibuprofen 800 mg TID.
The rates of discontinuations due to adverse clinical GI events per hundred patientyears over the entire period of study were as follows 3. A severity rating for each drug interaction, from minor to major. Each, however, has been directly compared with diclofenac.
People taking painkillers like etoricoxib have a slightly higher risk of heart problems such as fast heartbeat, chest pain, heart attack, heart failure or stroke.
Ask your doctor before use if you are taking the following medications:
However, since the drug is known to be substantially excreted by the kidney, the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Profound diuresis may cause fluid and electrolyte depletion.
Tegretol, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.
Overdose can cause lactic acidosis and low blood sugar.
Co and is now available in at least 62 countries throughout the world, but still awaits approval in the United States. The CHMP also noted that further studies need to be carried out to investigate the effects of these medicines in more detail when they are used for ankylosing spondylitis. Arcoxia has not been adequately studied in children. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.